AI Article Synopsis
Article Abstract
Coronavirus disease 2019 (COVID-19) is an unprecedented disease caused by highly pathogenic SARS-CoV-2 and characterized by extreme respiratory deterrence, pneumonia and immune damage. The phylogenetic analysis demonstrated the sequence similarity of SARS-CoV-2 with other SARS-like bat viruses. The primary source and intermediate host are not yet confirmed, although transmission from human to human is universally confirmed. The new SARS-CoV-2 virus reaches cells via ACE-2 and subsequently down-regulates ACE-2, leaving angiotensin II unbalanced in affected organs primarily in the lungs, heart, brain, and kidneys. As reported recently, numerous secondary complications i.e., neurological, nephrological, cardiovascular, gastrointestinal, immune, and hepatic complications, are associated with COVID-19 infection along with prominent respiratory disease including pneumonia. Extensive research work on recently discovered SARS-CoV-2 is in the pipeline to clarify pathogenic mechanisms, epidemiological features, and identify new drug targets that will lead to the development of successful strategies for prevention and treatment. There are currently no appropriate scientifically approved vaccines/drugs for COVID-19. Nonetheless, few broad-spectrum antiviral drugs, azithromycin were tested against COVID-19 in clinical trials, and finally, FDA approved emergency use of remdesivir in hospitalized COVID-19 patients. Additionally, administration of convalescent plasma obtained from recovered COVID-19 patients to infected COVID-19 patients reduces the viral burden via immunomodulation. This review analysis therefore concentrates primarily on recent discoveries related to COVID-19 pathogenesis along with a full description of the structure, genome, and secondary complication associated with SARS-CoV-2. Finally, a short and brief clinical update has been provided concerning the development of therapeutic medications and vaccines to counter COVID-19.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366108 | PMC |
| http://dx.doi.org/10.1016/j.lfs.2020.118105 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Model for Consolidating High-Risk Allergy Procedures in Clinic.
Ochsner J
January 2024
Department of Allergy and Immunology, Ochsner Clinic Foundation, New Orleans, LA.
Allergists perform a range of procedures with inherent risks of anaphylaxis. This study developed risk assessments for various procedures performed at our specialized referral center based on the frequency of epinephrine use during these procedures. During a 5.
View Article and Find Full Text PDFAntibiotic susceptibility testing and molecular characterization based on whole-genome sequencing of isolates from pediatric infections at the National Regional Medical Center of Southwest China during the COVID-19 pandemic.
Front Public Health
December 2024
Department of Laboratory Medicine, West China Second University Hospital, Sichuan University, Chengdu, China.
Background: is a transmitted respiratory pathogen that causes high morbidity and mortality in children, especially those under 5 years of age. During the implementation of population control measures for COVID-19 in mainland China, the detection rate in pediatric patients decreased. However, with the second wave of the COVID-19 pandemic (2022), the incidence of pneumococcal disease (PD) and even invasive pneumococcal disease (IPD) began to rise again.
View Article and Find Full Text PDFImpact of the COVID-19 Pandemic on the Implementation and Adoption of a Virtual Fracture Clinic Pathway: A Closed Loop Audit.
Cureus
December 2024
Department of Trauma and Orthopaedic Surgery, Our Lady of Lourdes Hospital Drogheda, Royal College of Surgeons in Ireland (RCSI) Hospital Group, Drogheda, IRL.
Introduction: Trauma and orthopedics departments have traditionally used face-to-face (FTF) fracture clinics for non-operative fractures. Developed in 2011, the virtual fracture clinic (VFC) was fully implemented at an institution during the COVID-19 pandemic to reduce in-person interactions.
Aims: First, the study aims to measure the percentage of non-operative patients triaged through the VFC when this was optional and re-audit after implementing a COVID-19-related policy change mandating VFC triage.
Biochemical profiles of patients with COVID-19 during the first and second waves in Ethiopia.
Front Immunol
December 2024
Department of Biochemistry, School of Biomedical Sciences, Jimma University, Jimma, Ethiopia.
Coronavirus disease 2019 (COVID-19) is a highly infectious disease caused by severe acute respiratory syndrome coronavirus 2. Nasopharyngeal swabs (NP swabs) were used for patients with COVID-19 who demonstrated serious clinical symptoms and disturbances in biochemical parameters. The biochemical profiles of these patients remain ambiguous and differ from wave to wave of COVID-19 infections.
View Article and Find Full Text PDFRisk and protective factors for coronavirus disease 2019 (COVID-19) in allergic rhinitis patients: a national survey in China.
Front Allergy
December 2024
Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Background: Several epidemiological studies have shown that allergic rhinitis (AR) patients are more susceptible to coronavirus disease 2019 (COVID-19).
Objective: We aim to investigate the risk factors for COVID-19 in AR patients.
Methods: A retrospective nationwide cohort study was conducted based on a questionnaire survey in China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!